Chemotherapy

Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches

Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches

[Breast Cancer: Targets and Therapy] A review of the potential of immunotherapy along and in combination with standard therapies for breast cancer, in particularly HER2-positive expressing subtypes.

ASCO Convenes Panel to Address Handling of Hazardous Drugs

ASCO Convenes Panel to Address Handling of Hazardous Drugs

By

An expert panel comprising physicians, pharmacists, researchers, and nurses compiles a set of standards for the safe handling of anticancer drugs.

9-Week Trastuzumab Course Not Noninferior to Standard Course for HER2+ Breast Cancer, But Does Offer a Benefit

9-Week Trastuzumab Course Not Noninferior to Standard Course for HER2+ Breast Cancer, But Does Offer a Benefit

By

Although 9 weeks of adjuvant trastuzumab was not noninferior to the standard 1 year of trastuzumab, researchers were surprised by the difference they did find between the 2 treatment courses.

Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer

Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer

By

In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.

Risk of Therapy-Related MDS, AML Increased by Use of Leukemogenic Chemotherapy Agents

Risk of Therapy-Related MDS, AML Increased by Use of Leukemogenic Chemotherapy Agents

By

Researchers sought to determine the association between chemotherapy, particularly platinum-based agents, and increased risk of tMDS/AML.

Neoadjuvant FOLFIRINOX a Better Option Than Surgery Plus Adjuvant Therapy in Pancreatic Cancer

Neoadjuvant FOLFIRINOX a Better Option Than Surgery Plus Adjuvant Therapy in Pancreatic Cancer

By

A decision-analysis was used to determine which treatment of BR/LA PDAC was more efficacious and more cost-effective: neoadjuvant FOLFIRINOX vs surgery with GEM/CAPE vs surgery with gemcitabine.

Apixaban Significantly Lowers Risk of Venous Thromboembolism in High-Risk Patients

Apixaban Significantly Lowers Risk of Venous Thromboembolism in High-Risk Patients

By

A clinical trial demonstrates that apixaban effectively decreases risk of VTE in patients with cancer; however, risk of major bleeding episodes may be higher.

Gene Expression-Based Identifier Predicts Risk, Treatment Outcomes for DLBCL Subtype

Gene Expression-Based Identifier Predicts Risk, Treatment Outcomes for DLBCL Subtype

By

Using a gene expression-based identifier, researchers found a method for discerning patients with DLBCL who may benefit from nonstandard therapies.

Classical Massage Mitigates CIPN Due to Adjuvant Chemotherapy for Breast Cancer

Classical Massage Mitigates CIPN Due to Adjuvant Chemotherapy for Breast Cancer

By

Researchers sought to determine if the complementary practice could prevent CIPN in patients receiving adjuvant chemotherapy for breast cancer.

Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations

Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations

By

Postchemotherapy hospitalizations and costs are higher for patients receiving highly emetogenic chemotherapy with no prophylaxis treatment.

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher

By

A meta-analysis of 14 randomized, controlled trials was conducted to determine if combining G-CSF with intensified chemotherapy improved overall survival.

Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified

Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified

By

Researchers analyzed data from more than 15,000 patients in Southern California with various cancers to identify clinical factors that contribute to the risk of developing chemotherapy-induced febrile neutropenia.

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

By

Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.

Nedaplatin Associated With Less Toxicity Than Cisplatin for MPE

Nedaplatin Associated With Less Toxicity Than Cisplatin for MPE

By

In this retrospective study, researchers sought to determine the efficacy of nedaplatin vs cisplatin for the treatment of malignancy-induced malignant pleural effusion.

Chemotherapy Side Effects in Women vs Men: Broader Range, More Severe

Chemotherapy Side Effects in Women vs Men: Broader Range, More Severe

By

An analysis of pooled data from 4 randomized controlled clinical trials revealed that male and female patients experience different chemotherapy side effects and at different severities, according to a poster presented at ESMO 2018 Congress.

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

By

Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.

No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers

No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers

By

Researchers investigated whether bleomycin posed concerns regarding pulmonary or operative outcomes following PC-RPLND in men treated with chemotherapy for IGCCCG good-risk germ cell cancers.

Strength and Hope for Women in the Mist of Cancer

Strength and Hope for Women in the Mist of Cancer

By

A review of the most feared effects of breast cancer treatment and resources to recommend to patients coping with these effects.

Delayed Administration Device for Pegfilgratim Safe, Effective in Preventing Grade 4 Neutropenia

Delayed Administration Device for Pegfilgratim Safe, Effective in Preventing Grade 4 Neutropenia

By

In a comparison study, the Onpro® device was found to be a safe and effective alternative to manual injection of pegfilgrastim in patients receiving chemotherapy.

Estimating Quality of Life Based on Cumulative Drug Toxicity in Colorectal Cancer

Estimating Quality of Life Based on Cumulative Drug Toxicity in Colorectal Cancer

By

Results of a study in which more than 100 patients with metastatic colorectal cancer completed EORTC-QLQ-C30 suggests an association between assessment of cumulative drug toxicities and predictions of quality of life for patients undergoing first-line chemotherapy for the disease.

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

By

Researchers sought to determine if nedaplatin could effectively manage malignancy-induced MPE in patients with cancer with less toxicity than cisplatin.

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma

By

An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.

New Formulations Improve Management of Chemotherapy-Induced Nausea and Vomiting

New Formulations Improve Management of Chemotherapy-Induced Nausea and Vomiting

By

In a recent report, researchers evaluate the efficacy of newer 5HT3-RAs for the prevention of CINV in patients with cancer receiving moderately or highly emetogenic chemotherapy.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

By

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

By

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

By

A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.

Additional Mammography Between Regular Screenings May Improve Breast Cancer Detection

Additional Mammography Between Regular Screenings May Improve Breast Cancer Detection

By

The MSP in Germany is designed to detect breast cancer during annually scheduled screenings and between the last negative and following screening among survivors.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

By

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score

Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score

By

In a randomization of women with early-stage breast cancer, researchers explored the potential benefits of chemotherapy for women whose Oncotype DX RS was midrange.

Antioxidant Interaction With Cancer Therapy

Antioxidant Interaction With Cancer Therapy

By

What is the concern with antioxidants and chemotherapy or radiation?

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs